T he role of natural killer T (NKT) cells in adipose tissue is a topic of much interest, as reports have suggested a correlation between depletion of the adipose-resident NKT (arNKT) cell population and chronic obesity. 1 Furthermore, it has been shown that arNKT cells are unique in terms of their function and phenotype; they produce anti-inflammatory and regulatory cytokines, and also induce the accumulation of FoxP3-expressing Tregs in adipose tissue. 2 There has been much speculation about whether these arNKT cells are a unique subset of the NKT cell repertoire or whether NKT cells take on a regulatory phenotype due to external cues in the adipose microenvironment. Recently, we provided the first evidence that arNKT cells are a distinct lineage of NKT cells that develop in the thymus. 3 Modification of the β chain of the NKT T cell receptor (TCR) has led to two discoveries: first, the discovery that a non-ligand binding domain of the NKT TCRβ chain is critical for CD1d recognition and NKT cell development; and second, the discovery that partial disruption of this domain, while permissive of CD1d recognition, results in the acquisition of an arNKT-specific phenotype in the thymus and preferential homing to adipose tissue.
NKT cells differ from conventional T cells in a number of ways, including restriction by CD1d-presented glycolipids rather than by major histocompatibility complex (MHC) molecules loaded with peptides. 4 The NKT TCR: CD1d interaction occurs in a parallel conformation, predominantly involving the TCRα chain, while the conventional TCR:MHC association involves both the α and β chains in a diagonal conformation. 5 In addition, while the recognition of pMHCs by conventional TCRs results in conformational changes in CDR loops, this conformational change is rarely observed upon binding of the NKT TCR to CD1d. 5 Altogether, these results suggest a weaker receptor: ligand interaction; however, the binding affinity of the NKT TCR to CD1d is actually higher than that of TCR:MHC interactions. 6 exhibited by pattern recognition receptors, occurring in a 'lock and key' manner, whereby the rigidity of the NKT TCR confers specificity to the CD1d:ligand interaction. 5, 7 In our recent study, we sought to explore whether a hydrophobic pocket formed by phenylalanine 108 (F108) on the NKT TCRβ chain was important for the stability of the NKT TCR heterodimer. 3, 8 This approach was used to reveal the extent to which receptor rigidity was important for the selection and development of NKT cells.
We investigated two mutations on the NKT TCRβ chain: Vβ8.2-F108Y, which is theorized to partially disrupt the hydrophobic interaction with the TCRα chain, and Vβ8.2-F108A, which is theorized to completely disrupt the interaction (Figure 1 ). T cell hybridoma lines expressing either mutation confirmed that the Vβ8.2-F108A, but surprisingly not the Vβ8.2-F108Y partial mutation, disrupted the ability of the receptor to recognize CD1d. Transgenic mice expressing the Vβ8.2-F108Y and Vβ8.2-F108A mutations, as well as control transgenic mice expressing a wild type (WT) Vβ8.2 were generated, and their T cell development was assessed. Both mutations were compatible with CD4 + and CD8 + T cell selection through interactions with MHC. In contrast, we observed a complete loss of NKT cells in mice expressing the Vβ8.2-F108A mutation. Interestingly, we observed a marked reduction in the NKT cell populations in the thymi, spleens and livers of the Vβ8.2-F108Y mice, suggesting that even though we did not observe measurable differences in CD1d recognition, partial disruption of the F108 hydrophobic domain resulted in significant changes in NKT cell development.
Our second discovery began with the analysis of the thymic development of NKT cells in the Vβ8.2-F108Y mice, which displayed a unique phenotype compared to the WT thymic NKT cells. Expression of the mutant TCR resulted in a significant decrease in the expression of the NKT cell maturation markers CD44 and NK1.1. In addition, the thymic NKT cells in Vβ8.2-F108Y mice expressed significantly lower levels of the transcription factor Promyelocytic Leukaemia Zinc Finger Protien (PLZF) regardless of their stage of development. Finally, we observed an increase in the expression of both PD-1 and the transcription factor NFIL3 (Figure 2 ). This phenotype was similar to the phenotype recently reported as being unique to arNKT cells. Therefore, we analyzed the arNKT population in Vβ8.2-F108Y mice and, remarkably, observed enrichment of this population compared to that in C57Bl/6 and Vβ8.2-F108 WT controls. This suggested that the acquisition of arNKT-specific markers in thymic NKT cells expressing the F108Y mutation might correlate with preferential homing to adipose tissue. To investigate this possibility, mixed bone marrow chimeras were generated by reconstituting 1:1 mixes of WT and Vβ8.2-F108Y donor bone marrow in Rag1 − / − mice. Astonishingly, while NKT populations in the spleen, thymus, and liver were mostly repopulated from the WT bone marrow, the arNKT cell population exhibited 90-100% reconstitution from the F108Y donor bone marrow. This suggested that the development of NKT cells exhibiting an adipose-resident phenotype in the thymus is closely associated with preferential homing to adipose tissue.
Finally, we sought to identify a mechanism by which the partial mutation of the NKT TCR hydrophobic pocket at residue TCRβ108 results in the development and trafficking of arNKT cells. While we did not observe a difference in the ability of NKT cells exhibiting the F108Y mutation to recognize an αGalCer-loaded CD1d tetramer, this did not preclude the development and trafficking of arNKT cells being affected by altered signaling through endogenous ligands or by molecules tertiary to the TCR complex. Using a Nur77-GFP reporter mouse, we showed that TCR signaling during development is comparable in NKT cells from WT and those from Vβ8.2-F108Y mice. We did, however, observe a deficiency in the activation of T cells from Vβ8.2-F108Y mice in response to staphylococcal enterotoxin B (SEB). SEB activates T cells specifically through TCR Vβ8, and the diminished activation in Vβ8.2-F108Y mice suggests that selection of NKT cell subsets could be controlled by signaling specific to the TCRβ chain.
There is evidence supporting the existence of distinct NKT subsets aside from arNKT cells. Differential expression of the transcription factors PLZF, RORγt and T-bet have been suggested to delineate NKT1, NKT2 and NKT17 cells, which have effector functions similar to their T helper counterparts. 9 Lymph node-resident NKT cells uniquely lack the IL-15 receptor and produce more IL-17, and their numbers appear (similarly to the numbers of arNKT cells) to be unaffected by PLZF deficiency. 10, 11 The production of IL-4 by hepatic NKT cells has been shown to mediate protection from melanoma metastasis, while thymic NKT cells, which produce similar levels of IL-4, fail to confer this protection. 12 In the context of these data, we think that systemically disrupting the NKT cell compartment fails to demonstrate the roles of subsets within the NKT cell population. Whether these subsets are developmentally and transcriptionally unique or tissue specific, or a combination of the two, we hypothesize that they interact both locally with their microenvironment as well as systemically to modulate immune responses in the context of a variety of diseases.
If the transcriptional program and tissue residency of NKT cells are vital to their role in protecting or promoting disease, it is equally important to determine how these subsets are selected to harness NKT cells for immunotherapy. Our recent study suggests that TCR signaling events that are TCRβ chain specific may play a role in the selection of unique NKT subsets. This is not a new idea, as Charles A. Janeway Jr. postulated over 20 years ago that conformational changes within the αβ TCR heterodimer may affect the recruitment of proteins to the TCR signaling complex. 13 Furthermore, a number of proteins outside the TCR complex have been shown to affect the phenotype of NKT cells. Mice deficient in WASp fail to upregulate NK1.1 in NKT cells, as do those mice deficient in the extracellular matrix protein osteopontin. 14, 15 Mice deficient in PKCθ display a decrease in their thymic NKT cell population, while mice deficient in BCL-10 show a decrease in their splenic NKT cell population. 16, 17 Mice heterozygous for PLZF exhibit 50-85% reductions of the thymic, splenic and hepatic NKT cell populations, but only a 5% reduction in the arNKT cell population. PLZF − / − mice display 80-90% reductions in the thymic, splenic and hepatic NKT populations, but only a~50% reduction in the arNKT cell compartment. 2 Altogether, these data suggest that a number of factors and pathways contribute to the selection of unique NKT cell subpopulations. Conformational changes in the NKT TCR that affect the recruitment of signaling molecules in response to various endogenous ligands, most of which remain unidentified, could represent an important area of study in relation to the development of particular subsets of NKT cells. Our Vβ8.2-F108Y model system can serve as an important tool in that regard. While it remains to be determined whether the mutation predicates the enhanced recognition of an endogenous antigen that selects for arNKT cells or whether it artificially disrupts secondary signaling in a way that favors arNKT cell development, the elucidation of either mechanism will be a pivotal step forward in our understanding of the development of unique NKT cell subsets.
